Skip to content

CRISPR Therapeutics

US · CRSP #2057 by market cap Listed 2016
39.10 +0.17 +0.44%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:54

About CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Founded
2013
CEO
Dr. Samarth Kulkarni, PhD
Employees
393
Headquarters
Zug, Zug, Switzerland
Fiscal year end
12-31
Website
crisprtx.com

Company profile

Exchange
US
Symbol
CRSP
Market-cap rank
#2057
Listing date
2016-10-19
Market cap
3.79B
Float cap
3.77B
Shares out
97.00M
Float shares
96.49M

Sectors & themes

Biotechnology ARK Portfolio AI medical concept stocks Gene Editing Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:54:43 · For reference only, not investment advice and not tailored to your situation.

CRISPR Therapeutics discussion 0 comments

Add a comment